Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole for irritability in autistic disorder (multicenter, double-blind, randomized, placebo-controlled, flexible-dose phase 2 trial)
2016-005111-40Phase 2
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Aripiprazole (Abilify) with Placebo (2 arms). Primary endpoints: ABC Irritability Subscale score, CGI-I score and 1 more.
02
Drugs
aripiprazole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2016-005111-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005111-40.